Raw Blood Detoxification Low-risk Group, The Treatment Of Myelodysplastic Syndrome By

objective: to observe the therapeutic efficacy of the Shengxuejiedu prescription in the treatment of low-danger MDS .Methods:27 patients were randomly divided into two groups: the SXJD group and the control group. Both the groups received the conventional treatment, and the SXJD group also took the Shengxuejiedu prescription. Compared the difference of the therapeutic efficacy between the two group in the improvement of symptom, blood picture and marrow picture.Result: the basic relief ratio of the SXJD group is 25%, the general availability ratio of the SXJD group is 82.5%; the basic relief ratio of the control group is 18.2%, the general availability ratio of the control group is 54.5%. the general availability ratio of the two groups are obviously different (P<0. 05) and in SXJD group , the therapeutic efficacy in improvement of the symptom is more obvious than the control group. Conclusion: the Shengxuejiedu prescription has obvious therapeutic efficacy for the low-danger MDS patients.